LENZ Therapeutics, Inc. $LENZ is Ally Bridge Group NY LLC’s 7th Largest Position

Core Viewpoint - Ally Bridge Group NY LLC significantly reduced its stake in LENZ Therapeutics by 48.9% during the third quarter, indicating a potential shift in investment strategy or confidence in the company [2] Institutional Investment Activity - Versant Venture Management LLC acquired a new stake in LENZ Therapeutics valued at approximately $123.76 million during the third quarter [3] - Adage Capital Partners GP L.L.C. increased its stake by 108.8% in the second quarter, now holding 1,122,738 shares worth $32.91 million after acquiring an additional 585,000 shares [3] - Franklin Resources Inc. raised its position by 6,756.1% in the third quarter, owning 587,084 shares valued at $27.35 million after acquiring 578,521 shares [3] - UBS Group AG increased its stake by 36.3% in the third quarter, now owning 1,201,616 shares valued at $55.97 million after acquiring 320,135 shares [3] - Hedge funds and institutional investors collectively own 54.32% of LENZ Therapeutics [3] Analyst Ratings - HC Wainwright maintained a "buy" rating for LENZ Therapeutics [4] - Wall Street Zen upgraded the stock from "sell" to "hold" [4] - Zacks Research downgraded the stock from "strong-buy" to "hold" [4] - Weiss Ratings reiterated a "sell (d-)" rating [4] - William Blair reissued an "outperform" rating [4] - The consensus rating for LENZ Therapeutics is "Moderate Buy" with a price target of $56.40 [4] Stock Performance - LENZ Therapeutics opened at $12.15, with a market cap of $380.17 million [5] - The stock has a 50-day simple moving average of $15.01 and a 200-day simple moving average of $25.99 [5] - The one-year low for the stock is $11.21, while the one-year high is $50.40 [5] - The company has a P/E ratio of -5.76 and a beta of 0.52 [5] Company Overview - LENZ Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies to improve vision in the U.S. [6] - Its product candidates, LNZ100 and LNZ101, are in Phase III clinical trials for treating presbyopia [6]